pharma news

News

Acadia, Harmony record late-stage rare disease failures

Biotechs Acadia Pharma and Harmony Biosciences both suffered setbacks in phase 3 trials of drugs for rare diseases, in one case ending the programme.

News

Moderna opens UK facility as drug pricing spat rumbles on

The UK government has celebrated the opening of Moderna's £150m vaccines facility, but storm clouds continue to gather on the issue of drug pricing.

News

Joy as uniQure Huntington's therapy clears pivotal trial

uniQure's gene therapy AMT-130 has cleared a trial in Huntington's, setting up filings and raising the prospect of a first treatment for the disease.

News

BMS eyes filings for myeloma 'celmod' iberdomide

Bristol Myers Squibb has said it hopes to be ready soon to file for approval of its multiple myeloma drug iberdomide after a positive phase 3 trial.

News

MSD's $349m alliance with Variational, and other AI news

MSD signs $345m alliance with Variational AI, plus updates on AI in drug discovery projects from Bio Protocol, Dalton Tx, Virginia Tech, and Insilico.

News

FDA knocks back Biogen's high-dose Spinraza

Biogen's efforts to defend its SMA business have been dealt a setback after the FDA declined to approve a high-dose version of Spinraza.

Acadia, Harmony record late-stage rare disease failures

Moderna opens UK facility as drug pricing spat rumbles on

Joy as uniQure Huntington's therapy clears pivotal trial

BMS eyes filings for myeloma 'celmod' iberdomide

MSD's $349m alliance with Variational, and other AI news

FDA knocks back Biogen's high-dose Spinraza

EU clears first drug therapy for rare disease cALD

Discover a new era of healthcare panel engagement: Grounded ...

pharma news

Editor's Picks